On Demo Day , organized by an accelerator of the Skolkovo School of Startups, NewStep defended its project in front of expert jury which consisted of companies that produce prostheses, doctors and investors. The startup also signed a memorandum of understanding with “Unicorn Capital Partners”, the management company of the venture fund “PharmMed Innovations”. The sum of investment which is stated in the memorandum after due diligence and conditions’ finalization can go up to 60 mln roubles.
NewStep is a developer of osteointegrative system of exoprosthetics. The system consists of fixing the exoprosthesis in the remaining bone of the residual limb with the help of an implant without using a limb-receiving sleeve. This fixation mechanism has been rapidly developing in the world for the past 10 years and is predicted to become the next step in the evolution of prosthetics. The solution allows to provide prosthetics to patients with short and defected residual limbs as well as to those who have trouble using limb-receiving sleeves and constitute between 10% and 25% of population with amputations.
NewStep has already finished developing exoprosthetics system for thighs, shins, shoulders, forearms and fingers. Moreover, specialised surgical instruments and medical protocols have been introduced in order to do surgeries to install the implantable components.
“The company has successfully conducted mechanical trials of the pilot model of thigh exoprosthetics and plans to have finished the system’s preclinical trials on animals by the end of 2024. Once the trials necessary to enter the market and certification-related procedures are over, NewStep plans to sell 150 systems in the first two years and increase the volume of sales to 2000 by 2030”, Oleg Lysak, the CEO of the “TechnoSpark” Company Group, announced.
NewStep is a developer of osteointegrative system of exoprosthetics. The system consists of fixing the exoprosthesis in the remaining bone of the residual limb with the help of an implant without using a limb-receiving sleeve. This fixation mechanism has been rapidly developing in the world for the past 10 years and is predicted to become the next step in the evolution of prosthetics. The solution allows to provide prosthetics to patients with short and defected residual limbs as well as to those who have trouble using limb-receiving sleeves and constitute between 10% and 25% of population with amputations.
NewStep has already finished developing exoprosthetics system for thighs, shins, shoulders, forearms and fingers. Moreover, specialised surgical instruments and medical protocols have been introduced in order to do surgeries to install the implantable components.
“The company has successfully conducted mechanical trials of the pilot model of thigh exoprosthetics and plans to have finished the system’s preclinical trials on animals by the end of 2024. Once the trials necessary to enter the market and certification-related procedures are over, NewStep plans to sell 150 systems in the first two years and increase the volume of sales to 2000 by 2030”, Oleg Lysak, the CEO of the “TechnoSpark” Company Group, announced.